Quality use of medicines in patients with chronic kidney disease

Abstract

Background: Chronic kidney disease (CKD) affects drug elimination and patients with CKD require appropriate adjustment of renally cleared medications to ensure safe and effective pharmacotherapy. The main objective of this study was to determine the extent of potentially inappropriate prescribing (PIP; defined as the use of a contraindicated medication or inappropriately high dose according to the kidney function) of renally-cleared medications commonly prescribed in Australian primary care, based on two measures of kidney function. A secondary aim was to assess agreement between the two measures. Methods: Retrospective analysis of routinely collected de-identified Australian general practice patient data (NPS MedicineWise MedicineInsight from January 1, 2013, to June 1, 2016; collected from 329 general practices). All adults (aged ≥18 years) with CKD presenting to general practices across Australia were included in the analysis. Patients were considered to have CKD if they had two or more estimated glomerular filtration rate (eGFR) recorded values < 60 mL/min/1.73m 2 , and/or two urinary albumin/creatinine ratios ≥3.5 mg/mmol in females (≥2.5 mg/mmol in males) at least 90 days apart. PIP was assessed for 49 commonly prescribed medications using the Cockcroft-Gault (CG) equation/eGFR as per the instructions in the Australian Medicines Handbook. Results: A total of 48,731 patients met the Kidney Health Australia (KHA) definition for CKD and had prescriptions recorded within 90 days of measuring serum creatinine (SCr)/estimated glomerular filtration rate (eGFR). Overall, 28, 729 patients were prescribed one or more of the 49 medications of interest. Approximately 35% (n = 9926) of these patients had at least one PIP based on either the Cockcroft-Gault (CG) equation or eGFR (CKD-EPI; CKD-Epidemiology Collaboration Equation). There was good agreement between CG and eGFR while determining the appropriateness of medications, with approximately 97% of the medications classified as appropriate by eGFR also being considered appropriate by the CG equation. Conclusion: This study highlights that PIP commonly occurs in primary care patients with CKD and the need for further research to understand why and how this can be minimised. The findings also show that the eGFR provides clinicians a potential alternative to the CG formula when estimating kidney function to guide drug appropriateness and dosing.

Five-Year Trends in Potential Drug Interactions with Direct-Acting Oral Anticoagulants in Patients with Atrial Fibrillation: An Australian-Wide Study

“…The data were de-identified and extracted from the electronic health records (EHRs) of general practices across Australia. Details about this dataset can be found elsewhere [17][18][19].…”

Stroke risk reassessment and oral anticoagulant initiation in primary care patients with atrial fibrillation: A ten‐year follow‐up

“…A total of 400 practice sites contributed data for this study. Details about this dataset can be found elsewhere 17‐24 . Patients newly diagnosed with AF from 1 January 2007 to 31 December 2008 (‘screening period’) and aged 18 years or more were included in this study.…”

“…Details about this dataset can be found elsewhere. [17][18][19][20][21][22][23][24] Patients newly diagnosed with AF from 1 January 2007 to 31 December 2008 ('screening period') and aged 18 years or more were included in this study. Baseline CHA 2 DS 2 -VA scores were calculated by assessing documented comorbidities until 31 December 2008.…”

Factors influencing oral anticoagulant use in patients newly diagnosed with atrial fibrillation

“…15 Details about this dataset can be found elsewhere. [15][16][17][18] Patients newly diagnosed with AF in Australian general practices between 1 January 2009 and 25 April 2019 were included in this study. Patients were defined as having a new AF diagnosis based on their first-ever recorded diagnosis date within the study period.…”

“…It includes patient demographics, diagnoses, prescribed medications, pathology test results, observations and reasons for encounters 15 . Details about this dataset can be found elsewhere 15‐18 …”